{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-421079","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2026-10-14T13:00:14+00:00","discovered_at":"2026-10-14T13:01:00.256993+00:00","generated_at":"2026-10-14T13:01:13.263403+00:00","sec_items":["1.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ultragenyx to sell FDA rare pediatric disease PRV for $203M in cash","bullets":["Asset purchase agreement signed October 8, 2026; unnamed buyer pays $203 million in cash at closing.","PRV was awarded by the FDA on September 17, 2026 with approval of FAYUVI (rebisufligene etisparvovec-hopf), also known as UX111.","FAYUVI/UX111 treats pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome Type A).","Closing subject to expiration or termination of the HSR antitrust waiting period; agreement to be filed with the FY2026 Form 10-K.","Pact includes customary representations, warranties, covenants and indemnification provisions subject to limitations."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-421079","json":"https://secwatch.observer/filing/0001193125-26-421079.json","markdown":"https://secwatch.observer/filing/0001193125-26-421079.md","text":"https://secwatch.observer/filing/0001193125-26-421079.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526421079/0001193125-26-421079-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526421079/rare-20261008.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-14T13:01:13.263403+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}